Contemporary post surgical management of differentiated thyroid carcinoma.

[1]  S. Larson,et al.  Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. , 2010, Thyroid : official journal of the American Thyroid Association.

[2]  B. Biondi,et al.  Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. , 2010, Thyroid : official journal of the American Thyroid Association.

[3]  Differentiating thyroid cells. , 2010, Thyroid : official journal of the American Thyroid Association.

[4]  M. Luster,et al.  A comparison of prognostic classification systems for differentiated thyroid carcinoma , 2009, Clinical endocrinology.

[5]  York Springer,et al.  Ajcc Cancer Staging Manual. 7th Ed. New , 2010 .

[6]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[7]  S. Larson,et al.  Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. , 2009, Thyroid : official journal of the American Thyroid Association.

[8]  S. Larson,et al.  Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation , 2009, Journal of Nuclear Medicine.

[9]  S. Straus,et al.  Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. , 2009, Thyroid : official journal of the American Thyroid Association.

[10]  E. Papini,et al.  Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. , 2009, European journal of endocrinology.

[11]  N. Mitsiades,et al.  Molecular pathology of thyroid cancer: diagnostic and clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[12]  Tuttle Rm.  Risk-Adapted Management of Thyroid Cancer , 2008 .

[13]  R. Tuttle,et al.  Medical management of thyroid cancer: a risk adapted approach , 2008, Journal of surgical oncology.

[14]  R. Tuttle,et al.  Follow up approaches in thyroid cancer: a risk adapted paradigm. , 2008, Endocrinology and metabolism clinics of North America.

[15]  A. Gafni,et al.  An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. , 2008, Endocrinology and metabolism clinics of North America.

[16]  S. Larson,et al.  Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008, Journal of Nuclear Medicine.

[17]  A. Gafni,et al.  A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors , 2008, Clinical endocrinology.

[18]  J. Tward,et al.  The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.

[19]  M. Nikiforova,et al.  Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis , 2008, Expert review of molecular diagnostics.

[20]  M. Santoro,et al.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[21]  M. Walter,et al.  The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study , 2007, Journal of Nuclear Medicine.

[22]  R. Tuttle,et al.  Papillary thyroid cancer: monitoring and therapy. , 2007, Endocrinology and metabolism clinics of North America.

[23]  T. Pilli,et al.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. , 2007, The Journal of clinical endocrinology and metabolism.

[24]  Electron Kebebew,et al.  The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer , 2007, Annals of surgery.

[25]  R. Tuttle,et al.  Investigational therapies for metastatic thyroid carcinoma. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[26]  N. Bufalo,et al.  Identifying a risk profile for thyroid cancer. , 2007, Arquivos brasileiros de endocrinologia e metabologia.

[27]  P. Hall,et al.  Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer , 2007, The British journal of surgery.

[28]  C. Harmer,et al.  Salivary gland toxicity after radioiodine therapy for thyroid cancer. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[29]  N. Katabi,et al.  Follicular variant of papillary thyroid carcinoma , 2006, Cancer.

[30]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[31]  R. Wahl,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[32]  Mithat Gonen,et al.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.

[33]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[34]  B. Biondi,et al.  Thyroid-hormone therapy and thyroid cancer: a reassessment , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[35]  Pedro Wesley Souza Do Rosário,et al.  Post I-131 Therapy Scanning in Patients With Thyroid Carcinoma Metastases: An Unnecessary Cost or a Relevant Contribution? , 2004, Clinical nuclear medicine.

[36]  Sendia Kim,et al.  Predicting outcome and directing therapy for papillary thyroid carcinoma. , 2004, Archives of surgery.

[37]  P. Hall,et al.  Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.

[38]  R. Kloos,et al.  Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. , 2002, The Journal of clinical endocrinology and metabolism.

[39]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[40]  C. Harmer,et al.  Testicular dose and fertility in men following I131 therapy for thyroid cancer , 2002, Clinical endocrinology.

[41]  C. Harmer,et al.  Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer , 2002, Postgraduate medical journal.

[42]  G. Csako,et al.  Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer , 2002, Annals of medicine.

[43]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[44]  S. Larson,et al.  Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.

[45]  A. Pinchera,et al.  131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. , 2001, The Journal of clinical endocrinology and metabolism.

[46]  Z. Baloch,et al.  Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. , 2001, Thyroid : official journal of the American Thyroid Association.

[47]  R. Kloos,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .

[48]  G. Wiseman,et al.  Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? , 2000, Thyroid : official journal of the American Thyroid Association.

[49]  M. Wichers,et al.  Testicular function after radioiodine therapy for thyroid carcinoma , 2000, European Journal of Nuclear Medicine.

[50]  I. Sugitani,et al.  Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. , 1999, Endocrine journal.

[51]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[52]  B. Cady,et al.  Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. , 1998, Archives of surgery.

[53]  P. Ladenson,et al.  Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. , 1998, Thyroid : official journal of the American Thyroid Association.

[54]  B. O'Sullivan,et al.  A comparison of different staging systems predictability of patient outcome , 1997, Cancer.

[55]  J. Bringer,et al.  Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. , 1996, The Journal of clinical endocrinology and metabolism.

[56]  S. Jhiang,et al.  Differentiated thyroid cancer long-term impact of initial therapy. , 1995, Transactions of the American Clinical and Climatological Association.

[57]  M. Dottorini,et al.  Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[59]  P. Ladenson,et al.  Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[60]  E. Bergstralh,et al.  Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. , 1992, Surgery.

[61]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[62]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[63]  B. D. Thompson,et al.  Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. , 1977, The British journal of radiology.

[64]  W. Beierwaltes,et al.  Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. , 1976, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  C. Lushbaugh,et al.  The effects of gonadal irradiation in clinical radiation therapy: A review , 1976, Cancer.

[66]  Haynie Tp,et al.  Hematologic changes observed following I-131 therapy for thyroid carcinoma. , 1963 .

[67]  M. Sonenberg,et al.  The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.